Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04907136 · ClinicalTrials.gov registry record · NA

Developing and Testing Health Warning Labels on the ENDS Device

A NA study of Electronic Cigarette Use, sponsored by Florida International University.

Recruiting
Registry status
NA
Development phase
80
Enrollment target
1
Study location

NCT04907136: Recruiting NA study of Electronic Cigarette Use, sponsored by Florida International University.

NCT04907136 is a NA study of Electronic Cigarette Use that is actively recruiting participants, run by Florida International University. The registered enrollment target is 80 participants, below the 207-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (61% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04907136, a NA study of Electronic Cigarette Use, is actively recruiting participants, sponsored by Florida International University.

RECRUITING
Registry status
NA
Development phase
80 participants
Enrollment target
1
Study location

Study Summary

In this project, after systematically developing electronic nicotine delivery systems (ENDS) pictorial health warning labels (HWLs), a proven clinical lab model will be used to examine and test their effect when these are placed on the ENDS device on a variety of subjective (e.g. satisfaction, harm perception, nicotine dependence, intention to quit) and objective outcomes (e.g. plasma nicotine, puff topography) in young adults.

Primary Outcome

Change in plasma nicotine level

Conditions Studied

Interventions

  • OTHER Preferred ENDS
  • OTHER Preferred ENDS with HWL

Study Locations (1)

Florida

  • Florida International University - Miami

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2023-12-13
Est. Completion 2027-04-30
Phase NA
Florida International University

89 total trials

What NCT04907136 shows while recruiting

NCT04907136 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 207-participant average among 15 other Electronic Cigarette Use trials with a reported enrollment target (61% lower).

The record links to 1 condition, with Electronic Cigarette Use appearing as the primary indexed condition, and to 2 interventions - of which Preferred ENDS is the first listed.

NCT04907136 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT04907136 about?

NCT04907136 is a clinical study titled "Developing and Testing Health Warning Labels on the ENDS Device". In this project, after systematically developing electronic nicotine delivery systems (ENDS) pictorial health warning labels (HWLs), a proven clinical lab model will be used to examine and test their effect when these are placed on the ENDS device on a variety of subjective (e.g. satisfaction, harm ...

What is the current status of trial NCT04907136?

This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2023-12-13. Estimated completion is 2027-04-30.

What conditions does trial NCT04907136 study?

This clinical trial studies the following conditions: Electronic Cigarette Use.

What interventions are being tested in trial NCT04907136?

The interventions under investigation include: Preferred ENDS (OTHER), Preferred ENDS with HWL (OTHER).

Who is sponsoring clinical trial NCT04907136?

This trial is sponsored by Florida International University, which has 89 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04907136 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Electronic Cigarette Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04907136's enrollment target sits among peer trials

80 9th of 15 higher than 7 of 15 other Electronic Cigarette Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Electronic Cigarette Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04907136, the US trial registry maintained by the National Library of Medicine. NCT04907136 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.